StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.75−0.06 (-3.31%)

Close on Nov 16, 2026Market cap $36.81MP/E –Yield –

Grace Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Grace Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.29M. For fiscal 2026 it was -$8.87M. The highest annual figure on record is -$8.87M in fiscal 2026.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$8.87M–
FY2025Mar 31, 2025-$14.90M–
FY2024Mar 31, 2024-$12.33M–
FY2023Mar 31, 2023-$15.91M–
FY2022Mar 31, 2022-$17.23M–
FY2021Mar 31, 2021-$14.32M–
FY2020Mar 31, 2020-$22.95M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$3.22M–
Q4 FY2026CQ1 2026Mar 31, 2026-$1.70M–
Q3 FY2026CQ4 2025Dec 31, 2025-$2.23M–
Q2 FY2026CQ3 2025Sep 30, 2025-$3.14M–
Q1 FY2026CQ2 2025Jun 30, 2025-$1.80M–
Q4 FY2025CQ1 2025Mar 31, 2025-$2.95M–
Q3 FY2025CQ4 2024Dec 31, 2024-$4.12M–
Q2 FY2025CQ3 2024Sep 30, 2024-$4.24M–
Q1 FY2025CQ2 2024Jun 30, 2024-$3.60M–
Q4 FY2024CQ1 2024Mar 31, 2024-$2.09M–
Q3 FY2024CQ4 2023Dec 31, 2023-$1.89M–
Q2 FY2024CQ3 2023Sep 30, 2023-$2.11M–
Q1 FY2024CQ2 2023Jun 30, 2023-$6.24M–
Q4 FY2023CQ1 2023Mar 31, 2023-$3.33M–
Q3 FY2023CQ4 2022Dec 31, 2022-$3.72M–
Q2 FY2023CQ3 2022Sep 30, 2022-$3.44M–
Q1 FY2023CQ2 2022Jun 30, 2022-$5.43M–
Q4 FY2022CQ1 2022Mar 31, 2022-$3.15M–
Q3 FY2022CQ4 2021Dec 31, 2021-$4.58M–
Q2 FY2022CQ3 2021Sep 30, 2021-$6.10M–
Q1 FY2022CQ2 2021Jun 30, 2021-$3.40M–
Q4 FY2021CQ1 2021Mar 31, 2021-$1.76M–
Q3 FY2021CQ4 2020Dec 31, 2020-$4.21M–
Q2 FY2021CQ3 2020Sep 30, 2020-$4.18M–
Q1 FY2021CQ2 2020Jun 30, 2020-$4.17M–
Q4 FY2020CQ1 2020Mar 31, 2020-$22.94M–
Q3 FY2020CQ4 2019Dec 31, 2019-$7.10M–
Q2 FY2020CQ3 2019Sep 30, 2019-$6.15M–
Q1 FY2020CQ2 2019Jun 30, 2019-$6.82M–
Q4 FY2019CQ1 2019Mar 31, 2019-$24.79M–

More Grace Therapeutics figures

See a number that looks wrong?